Evidence map›Paper›PMID 37175989›Full record

ReviewInternational journal of molecular sciences2023

Pax4 in Health and Diabetes.

Jenna Ko, Vivian A Fonseca, Hongju Wu

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. Functional Inactivation ofInternational journal of molecular sciences · 2026
    Article
  2. dentification and characterization of novelBMJ open diabetes research & care · 2025
    Article
  3. RareBiomedicines · 2025
    Article
  4. Article
  5. Article
  6. Review
  7. [Research advances in maturity-onset diabetes of the young].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2025
    Review
  8. Article
  9. Article
  10. The Role of the PAX Genes in Renal Cell Carcinoma.International journal of molecular sciences · 2024
    Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Jenna KoSection of Endocrinology, Department of Medicine, Tulane University Health Science Center, New Orleans, LA 70112, USA.
Vivian A FonsecaSection of Endocrinology, Department of Medicine, Tulane University Health Science Center, New Orleans, LA 70112, USA.
Hongju WuSection of Endocrinology, Department of Medicine, Tulane University Health Science Center, New Orleans, LA 70112, USA.ORCID 0000-0003-0926-8655
Tulane University · US

Funding

Pax4-induced alpha-to-beta cell conversionR01DK107412 · NIDDK · TULANE UNIVERSITY OF LOUISIANA · PI WU, HONGJU · 2016 to 2018
$1.0M
NIDDK NIH HHS DK107412NIDDK NIH HHS R01 DK107412
6 · The paper itself

Abstract

Paired box 4 (Pax4) is a key transcription factor involved in the embryonic development of the pancreatic islets of Langerhans. Consisting of a conserved paired box domain and a homeodomain, this transcription factor plays an essential role in early endocrine progenitor cells, where it is necessary for cell-fate commitment towards the insulin-secreting β cell lineage. Knockout of Pax4 in animal models leads to the absence of β cells, which is accompanied by a significant increase in glucagon-producing α cells, and typically results in lethality within days after birth. Mutations in Pax4 that cause an impaired Pax4 function are associated with diabetes pathogenesis in humans. In adulthood, Pax4 expression is limited to a distinct subset of β cells that possess the ability to proliferate in response to heightened metabolic needs. Upregulation of Pax4 expression is known to promote β cell survival and proliferation. Additionally, ectopic expression of Pax4 in pancreatic islet α cells or δ cells has been found to generate functional β-like cells that can improve blood glucose regulation in experimental diabetes models. Therefore, Pax4 represents a promising therapeutic target for the protection and regeneration of β cells in the treatment of diabetes. The purpose of this review is to provide a thorough and up-to-date overview of the role of Pax4 in pancreatic β cells and its potential as a therapeutic target for diabetes.

Indexed as

Diabetes MellitusIslets of LangerhansAnimalsCell DifferentiationGene Expression RegulationHomeodomain ProteinsHumansPaired Box Transcription FactorsHomeodomain ProteinsPaired Box Transcription FactorsPAX4 protein, humandiabetesisletsPax4α cellsβ cells

Identifiers

PMID37175989
PMCPMC10179455
OpenAlexW4376631014

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.